Chemotherapy after chidamide pretreatment in high-risk and refractory lymphoid malignancy: report of 16 cases
10.3760/cma.j.issn.1009-9921.2018.12.011
- VernacularTitle:西达本胺预处理后化疗的高危难治淋巴系统恶性肿瘤16例
- Author:
Shunhua HUANG
1
;
Fanyi MENG
;
Yaqin YU
;
Dana YAO
;
Qingxiu ZHONG
;
Hongyu CHEN
;
Xiaoguo WANG
Author Information
1. 523000,广东省东莞康华医院血液病中心
- Keywords:
Lymphoma;
Drug therapy,combination;
Chidamide;
High-risk;
Refractory
- From:
Journal of Leukemia & Lymphoma
2018;27(12):750-753
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the therapeutic effects of chemotherapy after chidamide pretreatment in 16 cases of high-risk and refractory lymphoid malignancy. Methods The efficacy and adverse reactions of 16 patients with high-risk and refractory lymphoid malignancy who received chidamide combined with chemotherapy after 3 days pretreatment of chidamide were analyzed. Results Sixteen patients included 6 males and 10 females, and the median age was 49.5 years old (23-88 years old). The median course of previous systemic chemotherapy was 4 (range 0-22). Among 14 patients who received induction chemotherapy, 7 patients achieved complete remission (CR), 7 patients achieved partial remission (PR). Fourteen patients had achieved clinical efficacy, and the overall response rate (ORR) was 100 %. After 2 cases had remission , the patients who entered this regimen for consolidation chemotherapy also had durable CR. The median follow-up time was 13 months (range 2-24 months) until December 2017. Nine cases had overall survival (OS), 7 cases died and 9 cases had progression-free survival. Common adverse effects of the chemotherapy included mild and controllable gastrointestinal reactions after chidamide. Conclusion Chemotherapy after chidamide pretreatment may improve the effect and prognosis of high-risk or refractory lymphoid malignancy.
